Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
Unmet needs in EGFR exon 20 insertion lung cancer, emphasizing the importance of early identification, selectivity against wild type EGFR, CNS activity, and mechanisms of resistance.
EP: 1.Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
EP: 2.Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
EP: 3.Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
EP: 4.EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
EP: 5.Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
EP: 6.EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
Now Viewing
EP: 7.Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
EP: 8.“Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say
Recent Videos
Related Content
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
